Last updated 9 days ago

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

1500 patients around the world
Available in Guatemala, Chile, United States
Merck Sharp & Dohme LLC
9Research sites
1500Patients around the world
This study is for people with
Prostate cancer
Castration resistant prostate cancer
Metastatic prostate cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Manzano 343, Recoleta, Región Metropolitana, Santiago
Clínica Universidad Católica del Maule
Recruiting
Dos Sur 1525, Talca, Maule
Instituto Oncológico FALP - UIDO
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Recruiting
Portugal 61, Santiago
Oncocentro APYS - Valparaíso
Recruiting
Avenida La Marina 1702, Viña del Mar, Valparaíso
CIDO SpA-Oncology
Recruiting
Temuco, Araucania, 4810218
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN
Recruiting
Guatemala, 01010
INTEGRA Cancer Institute - Oncologika, S.A
Recruiting
9 calle 4-52 zona 10, Edificio Integra 7mo. Nivel Guatemala Guatemala, 01010, Guatemala
Clínica Privada Dr. Rixci Ramirez
Recruiting
Guatemala, 01010
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy